KV Targets Citigroup Over $72M In Illiquid ARS
By Erin Coe ( February 25, 2009, 12:00 AM EST) -- KV Pharmaceutical Co. has targeted Citigroup Global Markets Inc. with a suit that accuses the bank of inducing the drug manufacturer to invest in auction rate securities and leaving it in the lurch with $72 million in now-illiquid ARS....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.